Effect of omeprazole on patient-reported outcome measures in uninvestigated heartburn: a multi-country, multi-center observational study

Background: Heartburn occurs predominantly in the upper gastrointestinal tract and is associated with gastroesophageal reflux disease (GERD) gastritis. Omeprazole most prescribed proton pump inhibitor class of medication to treat heartburn related clinical conditions. To compare efficacy omeprazole 40 mg (as a total daily dose) 20 using patient-reported outcome measures (PROMs) patients due various aetiologies like non-erosive disease, GERD, gastritis, dyspepsia, functional heartburn, gastro-duodenal ulcer.Methods: Naïve presenting symptoms were treated omeprazole. PROMs assessed based on short-form-leeds dyspepsia questionnaires (SF-LDQ), work productivity activity impairment (WPAI), relief obtained and, treatment satisfactory (TSQ).Results: A 18,724 (GERD gastritis; n=10,509) (Dr. Reddy’s [DO]/generic [GO]/branded [BO]) mg. Statistical comparative analysis showed significant improvement compared SF-LDQ, among heartburn. DO greater under ‘a lot’ ‘complete’ category.Conclusions: presented better as patient reported outcomes. This study highlights preferred intervention for improving quality life